This docum ent does not reflect the intent or official position of the bill sponsor or House of Representatives.
STORAGE NAME: h0459c.HHS
DATE: 1/24/2022
HOUSE OF REPRESENTATIVES STAFF ANALYSIS
BILL #: HB 459 Step-therapy Protocols
SPONSOR(S): Willhite and others
TIED BILLS: IDEN./SIM. BILLS: SB 730
REFERENCE ACTION ANALYST STAFF DIRECTOR or
BUDGET/POLICY CHIEF
1) Finance & Facilities Subcommittee 15 Y, 0 N Lloyd Lloyd
2) Health & Human Services Committee 19 Y, 0 N Lloyd Calamas
SUMMARY ANALYSIS
Insurers and health maintenance organizations (HMOs) use many cost containment strategies to manage
spending and utilization. For example, plans may limit the quantity of a drug that they will cover over a certain
period of time, require enrollees to obtain prior authorization from the plan before obtaining certain
prescriptions, procedures or treatments, or require enrollees to first try a preferred drug before obtaining a
more expensive drug. The last option, in which a health insurance plan requires a covered individual to try a
preferred drug or service before using a nonpreferred drug or service, is generally known as step therapy.
The Florida Insurance Code has largely been silent on the use of step therapy by insurers and HMOs. The only
current law addressing step therapy relates to repetition of step therapy protocols, in certain circumstances.
The bill defines “step therapy protocol” as a protocol or program that establishes the specific sequence in
which prescription drugs, medical procedures, or courses of treatment must be used to treat a health condition.
The bill also requires a process to receive a “protocol exemption”, which is a determination by an insurer or
HMO to exempt an insured patient from an existing step therapy protocol.
The bill requires an insurer or HMO to publish on its website, and provide to an insured in writing, a procedure
for an insured patient and health care provider to request a protocol exemption. The procedure must include:
The manner in which an insured patient or health care provider may request a protocol exemption;
The manner and timeframe in which the health insurer or HMO is required to authorize or deny a
protocol exemption request; and,
The manner and timeframe in which an insured patient may appeal the denial of a request.
The bill requires an insurer or HMO granting a protocol exemption to specify the prescription drug, medical
procedure, or course of treatment approved. Alternatively, an insurer or HMO denying a protocol exemption
request must provide a written explanation of the denial, including the clinical rationale supporting the denial.
The written explanation must also describe the procedure for appealing the determination by the insurer or
HMO.
The bill has no fiscal impact to state or local government.
The bill provides an effective date of July 1, 2022.
STORAGE NAME: h0459c.HHS PAGE: 2
DATE: 1/24/2022
FULL ANALYSIS
I. SUBSTANTIVE ANALYSIS
A. EFFECT OF PROPOSED CHANGES:
Background
Health Insurance
Health insurance is the insurance of human beings against bodily injury or disablement by accident or
sickness, including the expenses associated with such injury, disablement, or sickness.
1
Individuals
purchase health insurance coverage for the purpose of managing anticipated expenses related to
health or protecting themselves from unexpected medical bills or large health care costs. Managed
care is the most common delivery system for medical care today by health insurers.
2
Managed care
systems combine the delivery and financing of health care services by limiting the choice of doctors
and hospitals.
3
In return for this limited choice, however, medical care is less costly due to the
managed care network’s ability to control health care services. Some common forms of managed care
are preferred provider organizations
4
(PPO) and health maintenance organizations
5
(HMO).
Regulation of Insurers and Health Maintenance Organizations in Florida
The Office of Insurance Regulation (OIR) licenses and regulates the activities of insurers, HMOs, and
other risk-bearing entities,
6
while the Agency for Health Care Administration (agency) regulates the
quality of care by HMOs.
7
Before receiving a certificate of authority from the OIR, an HMO must receive
a Health Care Provider Certificate from the agency.
8
As part of the certification process used by the
agency, an HMO must provide information to demonstrate that the HMO has the ability to provide
quality of care consistent with the prevailing standards of care.
9
All persons who transact insurance in the state must comply with the Florida Insurance Code.
10
OIR
has the power to collect, propose, publish, and disseminate any information relating to the subject
matter of the Code,
11
and may investigate any matter relating to insurance.
12
Cost Containment in Health Insurance
Insurers use many cost containment strategies to manage medical and drug spending and utilization.
For example, plans may place utilization management requirements on certain procedures and
therapies and on the use of certain drugs on their formulary. These requirements can include limiting
the quantity of drug that they will cover over a certain period of time, requiring enrollees to obtain prior
authorization from their plan before filling a prescription (prior authorization), or requiring enrollees to
first try a preferred drug or service before obtaining an alternate drug or service for a particular medical
condition (step therapy).
Pharmacy Benefit Managers
1
S. 624.603, F.S.
2
Florida Department of Financial Services, Health Insurance and Health Maintenance Organizations, A Guide for Consumers,
http://www.myfloridacfo.com/Division/Consumers/understandingCoverage/Guides/documents/HealthGuide.pdf (last accessed Nov. 23,
2021).
3
Id.
4
S. 627.6471, F.S.
5
Part I of chapter 641, F.S.
6
S. 20.121(3)(a), F.S.
7
Part III of chapter 641, F.S.
8
S. 641.21(1), F.S.
9
S. 641.495, F.S.
10
S. 624.11, F.S. Chapters 624-632, 634, 635, 636, 641, 642, 648, and 651 constitute the Florida Insurance Code. S. 624.01, F.S.
11
S. 624.307(4), F.S.
12
S. 624.307(3), F.S. STORAGE NAME: h0459c.HHS PAGE: 3
DATE: 1/24/2022
Advances in pharmaceuticals have transformed health care over the last several decades. Many health
care problems are prevented, cured, or managed effectively using prescription drugs. As a result,
national expenditures for prescription drugs have grown from $122 billion in 2000 to $369.7 billion in
2019.
13
Health plan sponsors, which include commercial insurers, private employers, and government
plans, such as Medicaid and Medicare, spent $312 billion on prescription drugs in 2019, while
consumers paid $53.7 billion out-of-pocket for prescription drugs that year.
14
Health plan sponsors contract with pharmacy benefit managers (PBMs) to provide specified services,
which may include developing and managing pharmacy networks, developing drug formularies,
providing mail order and specialty pharmacy services, rebate negotiation, therapeutic substitution,
disease management, utilization review, support services for physicians and beneficiaries, and
processing claims.
15
Payments for the services are established in contracts between health plan
sponsors and PBMs.
16
For example, contracts will specify how much health plan sponsors will pay
PBMs for brand name and generic drugs. These prices are typically set as a discount off the average
wholesale price
17
for brand-name drugs and maximum allowable cost price for generic drugs, plus a
dispensing fee.
18
Prior Authorization
Under prior authorization, a health care provider is required to seek approval from an insurer before a
patient may receive specified prescription drugs under the plan. For example, most insurers or PBMs
will have a preferred drug list (PDL), which is an established list of one or more prescription drugs
within a therapeutic class deemed clinically equivalent and cost effective. Prior authorization would limit
an insured’s ability to obtain another drug within the therapeutic class that is not part of the PDL without
the insurer or PBM authorizing that drug.
Step Therapy Protocols
In some cases, plans require an insured to try one drug first to treat his or her medical condition before
they will cover another drug for that condition. For example, if Drug A and Drug B both treat a medical
condition, a plan may require doctors to prescribe the most cost effective drug, Drug A, first. If Drug A
does not work for a beneficiary, then the plan will cover Drug B. This form of cost containment is
commonly called step therapy. Step therapy is also known as fail-first as the insurer restricts coverage
of expensive therapies unless patients have already failed treatment with a lower-cost alternative.
Health plans use step therapy protocols differently for drugs indicated for different diseases. For
instance, plans apply protocols in 5 percent of decisions for cancer treatments and 36 percent of
decisions for non-cancer indications. They apply step protocols in 13 percent of decisions for drugs
treating rare conditions, and 33 percent for drugs used to treat more commonly occurring conditions.
One reason may be that drugs used for cancer or rare diseases typically have fewer therapeutic
substitutes than drugs indicated for other diseases.
19
13
Centers for Medicare and Medicaid Services, National Health Expenditure Data, Historical, Highlights,
https://www.cms.gov/files/document/highlights.pdf (last accessed Nov. 23, 2021).
14
Id.
15
Office of Program Policy Analysis & Government Accountability, Legislature Could Consider Options to Address Pharmacy Benefit
Manager Business Practices, Report No. 07-08 (Feb. 2007), https://oppaga.fl.gov/Products/ReportDetail?rn=07-08 (last accessed Nov.
23, 2021).
16
Id.
17
Average wholesale price is the retail list price (sticker price) or the average price that manufacturers recommend wholesalers sell to
physicians, pharmacies and others, such as hospitals.
18
Supra note 13.
19
“Variation In The Use Of Step Therapy Protocols Across US Health Plans," Health Affairs Blog, September 14, 2018,
https://www.healthaffairs.org/do/10.1377/hblog20180912.391231/full/ (last accessed Nov. 23, 2021). STORAGE NAME: h0459c.HHS PAGE: 4
DATE: 1/24/2022
Researchers report that there is mixed evidence on the impact of step therapy policies.
20
A review of
the literature found that there is little good empirical evidence for or against cost savings and utilization
reduction.
21
Some studies suggest that step therapy policies have been effective at reducing drug costs
without increasing the use of other medical services,
22
while other studies have found that step therapy
can increase total utilization costs over time because of increased inpatient admissions and emergency
department visits.
23
Florida Law on Step Therapy
Until recently, the Florida Insurance Code was silent on step therapy protocols, leaving insurers and
HMOs free to develop policies they felt appropriate.
In 2019, the Legislature adopted HB 843,
24
which included a specific and limited prohibition on the use
of step therapy by insurers and HMOs. Under this law, insurers and HMOs may not require a step
therapy protocol for a covered individual if they:
Were previously approved to receive a specific drug through completion of a step therapy
protocol by a separate health insurance plan; and,
Can provide documentation from the separate health insurance plan indicating that the specific
drug was paid for on the individual’s behalf during the past 90 days.
25
This protects individuals who switch from one health plan to another from having to repeat a step
therapy protocol.
Effect of Proposed Changes
The bill regulates the use of step therapy by insurers and HMOs. The bill applies to any protocol or
program that establishes the specific sequence in which prescription drugs, medical procedures, or
courses of treatment must be used to treat a health condition, called a “step therapy protocol.”
The bill requires an insurer or HMO to publish on its website, and provide to an insured in writing, a
procedure for an insured patient and health care provider to request a protocol exemption.
26
The
procedure must include:
The manner in which an insured patient or health care provider may request a protocol
exemption;
The manner and timeframe in which the health insurer or HMO is required to authorize or deny
a protocol exemption request; and,
The manner and timeframe in which an insured patient may appeal the denial of a request.
Under the bill, an insurer or HMO granting a protocol exemption must specify the prescription drug,
medical procedure, or course of treatment approved. Alternatively, an insurer or HMO denying a
protocol exemption request must provide a written explanation of the denial, including the clinical
rationale supporting the denial. The written explanation must also describe the procedure for appealing
the determination by the insurer or HMO.
The bill provides an effective date of July 1, 2022.
20
Rahul K. Nayak and Steven D. Pearson, The Ethics Of 'Fail First’: Guidelines and Practical Scenarios for Step Therapy Coverage
Policies, Health Affairs 33, No.10 (2014):1779-1785, https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2014.0516 (last accessed
Nov. 28, 2021).
21
Motheral, B.R., Pharmaceutical Step Therapy Interventions: A Critical Review of the Literature, Journal of Managed Care Pharmacy
17, no. 2 (2011) 143-55, http://www.jmcp.org/doi/pdf/10.18553/jmcp.2011.17.2.143 (last accessed Nov. 23, 2021).
22
Supra note 20 at pg. 1780.
23
Id.
24
Ch. 2019-138, L.O.F.
25
Ss. 627.42393 and 641.31(46), F.S.
26
A “protocol exemption” is a determination by an insurer or HMO to exempt an insured patient from an existing step therapy protocol. STORAGE NAME: h0459c.HHS PAGE: 5
DATE: 1/24/2022
B. SECTION DIRECTORY:
Section 1: Amends s. 627.42393, F.S.; relating to step-therapy protocol.
Section 2: Amends s. 641.31, F.S.; relating to health maintenance contracts.
Section 3: Provides an effective date of July 1, 2022.
II. FISCAL ANALYSIS & ECONOMIC IMPACT STATEMENT
A. FISCAL IMPACT ON STATE GOVERNMENT:
1. Revenues:
None.
2. Expenditures:
None.
B. FISCAL IMPACT ON LOCAL GOVERNMENTS:
1. Revenues:
None.
2. Expenditures:
None.
C. DIRECT ECONOMIC IMPACT ON PRIVATE SECTOR:
None.
D. FISCAL COMMENTS:
None.
III. COMMENTS
A. CONSTITUTIONAL ISSUES:
1. Applicability of Municipality/County Mandates Provision:
Not Applicable. This bill does not appear to affect county or municipal governments.
2. Other:
None.
B. RULE-MAKING AUTHORITY:
The OIR has sufficient rulemaking authority to implement the provisions of the bill.
C. DRAFTING ISSUES OR OTHER COMMENTS:
None.
IV. AMENDMENTS/ COMMITTEE SUBSTITUTE CHANGES
STORAGE NAME: h0459c.HHS PAGE: 6
DATE: 1/24/2022